Our Corporate Values
Strive for Good Science and Strong Processes
MMS is committed to making sound decisions based on strong scientific principles, internal expertise, and applicable regulation. As an organization, MMS emphasizes and values strong internal processes through defining, following, and improving upon the steps that lead to high-quality deliverables.
Value Talent – Find, Attract, Enhance and Retain
MMS recognizes that a talented staff is what drives our business forward. Identifying and attracting top talent and continual training to strengthen core skills are essential to core mission. At MMS, enthusiasm, collaboration, and teamwork is fostered, knowing that a global and diverse talent pool makes the company stronger.
Wow the Customer
MMS believes in delivering value beyond the competition. Each sponsor and researcher that MMS partners with is important and their goals relevant. MMS will strive to exceed their expectations by maintaining a customer focus throughout the project lifecycle, ensuring the customer experience is positive, building trust and forging long-term relationships.
Bring a Sense of Urgency and Leadership (SOUL)
MMS promotes the importance of SOUL through a healthy work environment and as a requirement for providing added value to clients. The SOUL of MMS comes to life as project work is completed on time and as risks and solutions are identified proactively. At MMS, each colleague takes responsibility for the success of every project.
“MMS does a great job of supporting colleague development through extensive training, job shadowing, mentoring, and teamwork activities.”
Suggested For You
perspectives
April 20th, 2026
The FDA Drug Shortage List Signals Deeper Concerns for the US Medicine Supply Chain
perspectives
April 15th, 2026
Decision-Making in Early-Phase Oncology Trials: Navigating Uncertainty with Evidence Frameworks
perspectives
April 8th, 2026
Four Pillars of My Success as a Clinical Trial Transparency Specialist
webinar
March 26th, 2026
Making the Right Decisions With Incomplete Evidence in Early-Phase Oncology Trials
perspectives
March 25th, 2026
REMS and Labeling Are Strategic Design Decisions, Not Late-Stage Add-Ons
perspectives
March 12th, 2026
AI in Pharma: Autopilot Is Not the Same as Removing the Pilot
webinar
April 30th, 2026
Inside FDA REMS Decision-Making: A Fireside Chat for Sponsors
perspectives
March 3rd, 2026
Modeling and Simulation in Clinical Trials: A Practical Approach to De-Risking Study Design
perspectives
February 25th, 2026
Integrating AI and Automation Into Clinical Trial Operations With Discipline and Transparency
perspectives
February 10th, 2026
A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development
news
February 5th, 2026
MMS Appoints FDA Alum Dr. Somya Dunn as Senior Medical Director, Safety Risk Management to Expand Leadership in REMS and Pharmacovigilance Solutions
perspectives
February 3rd, 2026
A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development